Cervical Cancer Screening Tests

HPV 16/18 Genotyping

ASCCP Practice Guidelines have determined that in cytology negative women 30 years and older who are HPV DNA positive, molecular genotyping assays that detect HPV 16 and 18 would be clinically useful for determining which women should be referred for immediate colposcopy, and which could be followed-up with repeat cytology and high-risk HPV testing in 12 months.

HPV 16 and 18 infections account for 70% of all cervical cancer. HPV genotypes 16 and 18 should warrant special consideration given their significant link to cervical cancer. Cervista HPV 16/18 Genotyping is now available on the ThinPrep® vial.

Pap testing: More Than Just “Routine”

ThinPrep® and SurePath™ Liquid-Based Paps are:

  1. FDA-approved
  2. Refer fewer women to colposcopy
  3. Resulted within 48 hours
  4. Able to perform HPV testing from
    the same vial

SurePath™: Simplified collection, with 100% of the collected sample transferred to the vial for processing in the lab. Allows physician to perform Pap tests in a wide variety of clinical presentations (e.g. blood, mucous and inflammation) with maximum confidence in the result.

ThinPrep® Advanced Imaging Technology: The ThinPrep® Imaging System has been added to our offerings to enhance the current ThinPrep® cervical cancer screening test.

Computer imaging technology is used to prescreen ThinPrep paps and identify key areas for subsequent review by our Cytotechnologists. This dual review screening increases detection of Cervical Dysplasia and provides for a higher level of diagnostic accuracy than the ThinPrep pap alone.

High Risk HPV Reflex Testing

ACOG Practice Guidelines recommend that women be tested for HPV (human papillomavirus) in tandem with Pap smears beginning at age 30. High risk HPV reflex testing is available with the ThinPrep® liquid-based Pap. PeaceHealth Laboratories also automatically holds cervical specimens for a minimum of 30 days in the event that reflex testing is requested after we notify a physician of a potential concern related to HPV.